Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

The FDA has granted approval to the menin inhibitor ziftomenib (Komzifti) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations with no ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

Legend Biotech’s stock has drawn renewed analyst attention after the company’s Fair Value estimate held steady at $75.06 per share. Although the revenue growth forecast has edged down slightly and the ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent ...

Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep® ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ...